Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 27, 24 | -0.33 Increased by +23.26% | -0.43 Increased by +23.26% |
| Nov 7, 23 | -0.39 Increased by +18.75% | -0.42 Increased by +7.14% |
| Aug 10, 23 | -0.32 Increased by +23.81% | -0.46 Increased by +30.43% |
| May 11, 23 | -0.4 Increased by +9.09% | -0.48 Increased by +16.67% |
| Feb 28, 23 | -0.43 Increased by +24.56% | -0.5 Increased by +14% |
| Nov 10, 22 | -0.48 Increased by +40.74% | -0.5 Increased by +4% |
| Aug 11, 22 | -0.42 Increased by +30% | -0.47 Increased by +10.64% |
| May 12, 22 | -0.44 Decreased by -15.79% | -0.58 Increased by +24.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 362 K Increased by +18 K% | -20.67 M Increased by +12.1% | Decreased by -5.71 K% Increased by +99.51% |
| Jun 30, 23 | 6 K Decreased by -25% | -16.06 M Increased by +18.96% | Decreased by -267.68 K% Decreased by -8.05% |
| Mar 31, 23 | 21 K Decreased by -34.38% | -18.39 M Increased by +5.01% | Decreased by -87.58 K% Decreased by -44.75% |
| Dec 31, 22 | -110 K Decreased by -103.36% | -20.23 M Increased by +15.33% | Increased by +18.39 K% Increased by +2.62 K% |
| Sep 30, 22 | 2 K Decreased by -98.73% | -23.52 M Increased by +29.83% | Decreased by -1.18 M% Decreased by -5.43 K% |
| Jun 30, 22 | 8 K Decreased by -94.19% | -19.82 M Increased by +20.17% | Decreased by -247.74 K% Decreased by -1.27 K% |
| Mar 31, 22 | 32 K Decreased by -96.18% | -19.36 M Decreased by -30.25% | Decreased by -60.5 K% Decreased by -3.31 K% |
| Dec 31, 21 | 3.28 M Increased by +41.72% | -23.89 M Decreased by -124.91% | Decreased by -728.85% Decreased by -58.7% |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.